Home Astellas Pharma

Astellas Pharma

Looking to expand your partner network with leading companies like Astellas Pharma? Consider joining Inpart's global network for free.

Stay informed about the latest news about Astellas by subscribing to our newsletter.

What is Astellas best known for?

Astellas is a pharmaceutical company recognized for its research and development of innovative therapies. They specialize in urology, with notable contributions in prostate cancer and overactive bladder treatments like Xtandi and Myrbetriq.

Where is Astellas located?

Astellas has its global headquarters located in Tokyo, Japan. Additionally, the company has various offices and facilities worldwide, including in North America, Europe, and Asia, to support its operations and research activities in different regions.

Got a news story for us related to Astellas? Send it to us here.

Latest Posts

Best in Biotech 27 Feb 2024

Japan’s ten hottest biotech companies in healthcare

While Japan historically lacked foreign investment the field is becoming more dynamic. Discover ten essential biotech companies in Japan.

February 27, 2024 - 12 minutesmins - By Jules Adam

Geographic atrophy treatment: Apellis' Syfovre vs. Astellas' Izervay.

In Depth 22 Nov 2023

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […]

November 22, 2023 - 8 minutesmins - By Willow Shah-Neville

News and Trends 9 Jun 2023

Astellas developing new gastric cancer drug

Astellas Pharma Inc. has submitted a new drug application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for zolbetuximab. Zolbetuximab is a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. If approved, […]

June 9, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 8 Jun 2023

Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases

Gene therapy company Kate Therapeutics Inc. (KateTx), has emerged from stealth mode with a $51 million Series A financing. In addition, the company has granted Astellas Pharma Inc. an exclusive, worldwide license to develop, manufacture and commercialize KT430 to treat X-linked myotubular myopathy (XLMTM). There are a large number of genetically defined and complex muscle […]

June 8, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 15 May 2023

New menopause drug gets FDA approval

The U.S. Food and Drug Administration has approved Astellas Pharma’s Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Astellas Pharma US, Inc.’s Veozah is the first neurokinin 3 (NK3) receptor antagonist approved by the FDA to treat moderate to severe hot flashes from […]

May 15, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 5 May 2023

Promising results from phase 3 prostate cancer study

Astellas Pharma Inc. and Pfizer Inc. have announced trial results from a phase 3 study on prostate cancer. The results showed XTANDI (enzalutamide) plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide, as assessed by the primary endpoint of metastasis-free survival (MFS) in men with non-metastatic hormone-sensitive prostate […]

May 5, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 2 May 2023

Astellas eyes ophthalmology field with $5.9B Iveric Bio takeover

Astellas Pharma Inc., through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio, Inc., for $40 per share in cash for a total equity value of approximately U.S. $5.9 billion. Iveric Bio will become an indirectly wholly-owned subsidiary of Astellas. […]

May 2, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 14 Mar 2023

Astellas menopause study meets endpoints but leukemia drug disappoints

There was good and bad news this week from Japanese company Astellas Pharma Inc. as one of its trials yielded positive results, while another didn’t meet its endpoints. Astellas Pharma announced pivotal phase 3 results for its study of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor […]

March 14, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 10 Feb 2023

Beyond Biotech podcast 33: Astellas Pharma, Innovation Agency Lithuania, 4basebio

This week, our guests are Romualda Stragienė, director at Innovation Agency Lithuania and Andrius Sliuzas, export key account manager of high tech industries at Innovation Agency Lithuania; 4basebio CEO Heikki Lanckriet; and Yoshitsugu Shitaka, chief scientific officer at Astellas. 4basebio 4basebio, a spinout of 2Invest AG in 2020, is a life sciences company engaged in […]

February 10, 2023

News and Trends 11 Jan 2023

Biotech in Asia: looking forward to 2023

Masahiko Hayakawa, head of targeted protein degradation at Astellas Pharma Inc., gives us some insights into the state of the biopharma industry in 2023. Astellas is a Japanese headquartered pharmaceutical company active in more than 70 countries around the world. It promotes a ‘focus area approach’ designed to identify opportunities for the continuous creation of […]

January 11, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 9 Jan 2023

Selecta and Astellas sign LOPD treatment agreement

Selecta Biosciences, Inc. and Astellas Pharma Inc. have announced an exclusive licensing and development agreement for IdeXork (Xork). Xork is being studied as a potential next generation immunoglobulin G (IgG) protease that will be developed by Astellas for use with AT845, an investigational, adeno-associated virus (AAV)-based treatment for late-onset Pompe disease (LOPD) in adults. Pompe […]

January 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

Japanese companies look to reduce environmental impact

Japanese companies Astellas Pharma Inc., Eisai Co., Ltd., Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited have agreed a collaboration to reduce the environmental impact of pharmaceutical packaging. Based on the agreement, the four companies will aim to promote the use of more environmentally-friendly packaging for pharmaceutical products by sharing knowledge on packaging technologies […]

December 22, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Astellas Pharma

What is Astellas best known for?

Where is Astellas located?

Japan’s ten hottest biotech companies in healthcare

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Astellas developing new gastric cancer drug

Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases

New menopause drug gets FDA approval

Promising results from phase 3 prostate cancer study

Astellas eyes ophthalmology field with $5.9B Iveric Bio takeover

Astellas menopause study meets endpoints but leukemia drug disappoints

Beyond Biotech podcast 33: Astellas Pharma, Innovation Agency Lithuania, 4basebio

Biotech in Asia: looking forward to 2023

Selecta and Astellas sign LOPD treatment agreement

Japanese companies look to reduce environmental impact

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!